PDCD1 and neoplasm: More recently, Ford et al. [23] developed myCAF-rich murine tumour models and showed that Setanaxib could be used to effectively overcome myCAF-mediated T-cell exclusion from tumours and potentiate response to anti-tumour vaccination and anti-PD-1 immunotherapies [23].